Carla R.
- Country
- Portugal
- Department
- Gastrology
Research Overview
- Evaluation of Semaglutide in Patients with Non-Cirrhotic Non-Alcoholic Steatohepatitis and Fibrosis Stages 2 or 3: A Randomized, Placebo-Controlled Trial
- Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of Fazirsiran in Alpha-1 Antitrypsin Deficiency-Associated Liver Disease with METAVIR F1 Fibrosis
- Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of Lanifibranor in Adults with Non-Cirrhotic Non-Alcoholic Steatohepatitis and Fibrosis Stages F2/F3
Data & Insights
Has run more than one trial at 63 of 176 partner sites.
Specializations
Liver Disease & Metabolism
The investigator specializes in the treatment of non-alcoholic steatohepatitis (NASH), with particular focus on patients with varying stages of liver fibrosis. Their research encompasses innovative therapeutic approaches using both lanifibranor and semaglutide for NASH management.
- NASH resolution strategies
- Liver fibrosis treatment
- Metabolic liver disease management
Genetic Liver Disorders
The investigator conducts research in alpha-1 antitrypsin deficiency-associated liver disease (AATD-LD), evaluating novel therapeutic approaches including fazirsiran. Their work focuses on addressing both liver manifestations and associated pulmonary complications.
- AATD liver disease treatment
- Liver fibrosis assessment
- Pulmonary function monitoring
Allergic Conditions
The investigator studies pharmacological interventions for allergic disorders, particularly focusing on urticaria and allergic rhinitis. Their research includes evaluation of rupatadine in patients with varying degrees of hepatic function.
- Antihistamine therapeutics
- Hepatic impairment studies
- Allergic disease management
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.